NASDAQ · PTCT

PTC Therapeutics, Inc.

$76.82 -$1.63 (-2.08%) 1D After hours
Charting by TradingView

Key Metrics

$6.51B
Market cap
—
P/E · TTM
$827.11M
Revenue · TTM
−$186.73M
Net income
EPS · TTM $-2.16
Dividend yield —
Free cash flow −$226.28M
Beta · 1Y 0.73
EBITDA · TTM −$188.66M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 8
    The stock moved +14.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 8
  • Mar 9
    The stock moved +8.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 9

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$6.51B
Enterprise value$4.90B
Shares outstanding82.9M
52-wk range$43.18 – $90.87
Avg volume · 20D892.7K
Net cash $1.61B
Book value / share$-2.09
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About PTC Therapeutics, Inc.
IPO dateJun 20, 2013
Employees991

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S7.87
P/FCF—
EV/EBITDA—
EV/Sales5.93
Graham №—

Profitability

Gross —
Operating -28.5%
Net -22.6%
FCF -27.4%
ROE / ROIC 29.2% · 10.5%

Financial Health

Current ratio2.44
Quick ratio2.36
Debt / equity-1.59
Debt / EBITDA -1.52
Net cash $1.61B
Working capital$1.33B

Cash Flow · TTM

Operating CF −$217.95M
Capex −$8.33M
Free cash flow −$226.28M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

0.4
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings